ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 562

Low Inflammation on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis That Achieved Sustained Clinical Remission on Adalimumab

Paul Emery1, Gerd R. Burmester2, Esperanza Naredo3, Ivan Lagunes Galindo4, Ying Zhang5, Xin Wang5, Maja Hojnik6 and Philip G. Conaghan7, 1University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, 2Charité-University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, 3Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 4AbbVie Inc., North Chicago, IL, 5AbbVie, North Chicago, IL, 6AbbVie, Ljubljana, Slovenia, 7University of Leeds, Leeds, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Adalimumab, Inflammation, Magnetic resonance imaging (MRI), remission and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, October 21, 2018

Session Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

ACR and EULAR recommend bDMARD tapering in patients (pts) with rheumatoid arthritis (RA) who achieved stable clinical remission. Yet, there are limited systematically collected data on objective magnetic resonance imaging (MRI)-assessed levels of musculoskeletal inflammation, especially tenosynovitis, in RA pts in stable clinical remission with previous data derived from a range of cohorts with differing definitions of clinical remission.The purpose of the analysis was to evaluate within the PREDICTRA study the extent of disease control, in particular MRI inflammation, in RA pts in DAS28-based stable clinical remission attained on adalimumab (ADA) at the standard dosing of 40 mg every other week (eow).

Methods:

PREDICTRA is a multicenter, randomized, double-blind study generating data on pt and disease characteristics that may predict the clinical course of ADA dose-tapering for RA pts in stable clinical remission. RA pts with DAS28-CRP or -ESR <2.6 for ≥6 months following treatment with originator ADA 40 mg eow for ≥12 months in clinical practice were eligible to enter a 4-week (wk) open-label lead-in study period with continued standard ADA dosing. Pts must have had confirmed DAS28-ESR <2.6 at the beginning and end of the lead-in period and quality-verified MRI of the most affected or, if both equally affected, the dominant hand to be eligible for randomization. Study assessments included multiple measures of disease activity (SJC28 and 68, TJC28 and 68, DAS28, CDAI, SDAI, patient’s and physician’s global assessment of disease activity), physical function (HAQ-DI, SF-36 PCS), and OMERACT RAMRIS scores for synovitis, tenosynovitis, bone marrow edema and erosions. Data of the randomized pts at the end of the lead-in period are presented.

Results:

Of the 149 pts that entered the lead-in period, 122 (82%) were randomized. The randomized pts were 75% female, mean age 59.7±10.3 years, RA duration 12.8±9.8 years, prior ADA exposure 5.1±3.0 years, and DAS28 remission duration 2.2±2.1 years. Most pts received concomitant methotrexate (83.6%; mean dose 13.2 mg weekly) and few received concomitant corticosteroids (9.8%; mean dose 3.2 mg daily). Very low disease activity was observed in terms of clinical measures and MRI inflammation scores (synovitis [3.5±3.13], osteitis [1.0±2.01], tenosynovitis [2.7±2.7]). The mean MRI erosion score was low given the disease duration, and physical function scores were within normal ranges (Table).

Conclusion: Pts with long-standing RA randomized to the tapering phase of the PREDICTRA study based on sustained DAS28-based clinical remission on prior standard dose ADA therapy showed very low levels of clinical disease activity and normal physical function. This concurred with low MRI inflammation scores, especially for osteitis and tenosynovitis, the latter pathology being reported for the first time in RA clinical remission pts.

Table: Summary of Patient Characteristics

Patient Characteristic (N=122)

Mean (SD)*

Duration of prior adalimumab, years

5.1 (3.0)

Duration of remission, years

2.2 (2.0)

Concomitant csDMARDs dose, mg

Methotrexate (weekly)

Hydroxychloroquine (daily)

Sulfasalazine (daily)

13.2 (5.5)

228.6 (75.6)

750.0 (288.7)

Concomitant oral corticosteroids dose, mg (daily)

3.2 (1.7)

Anti-cyclic citrullinated peptide (ACCP), Unit

ACCP positive, n (%)

286.6 (206.4)

63 (52.9)

Rheumatoid factor (RF), KU/L

RF positive, n (%)

139.5 (395.4)

90 (76.3)

C-reactive protein (CRP), mg/L

5.3 (28.0)

Erythrocyte sedimentation rate (ESR), mm/hr

11.4 (8.4)

Tender joint count (TJC) 68

0.3 (0.6)

Swollen joint count (SJC) 66

0.1 (0.3)

DAS28 (ESR)

1.7 (0.6)

Clinical Disease Activity Index (CDAI)

1.3 (1.4)

Simplified Disease Activity Index (SDAI)

1.8 (3.0)

Patient’s Global Assessment of Disease Activity –VAS, 0-100 mm

6.4 (8.9)

Physician’s Global Assessment of Disease Activity – VAS, 0-100 mm

3.7 (5.0)

Pain – VAS, 0-100 mm

8.5 (11.5)

HAQ-DI

0.3 (0.4)

SF-36 MCS

54.4 (7.7)

SF-36 PCS

50.1 (7.8)

MRI OMERACT scores

Synovitis, Range 0-24

Osteitis, Range 0-75

Tenosynovitis, Range 0-30

Erosion, Range 0-250

3.5 (3.1)

1.0 (2.0)

2.7 (2.7)

21.4 (26.9)

*All values are Mean (SD) unless otherwise specified

ACCP = Anti-cyclic citrullinated peptide; CRP = C-reactive protein; ESR = Erythrocyte sedimentation rate; EAMs = extra-articular manifestations; HAQ-DI = Health Assessment Questionnaire – Disability Index; IBD = inflammatory bowel disease; MCS = mental component summary; OMERACT = Outcome Measures in Rheumatoogy; PCS = physical component summary; Pts = patients; RF = rheumatoid factor; SD = standard deviation; SF-36=Short form 36-item health survey; VAS = Visual Analogue Scale.


Disclosure: P. Emery, AbbVie, Bristol-Myers Squibb, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB, 2, 5; G. R. Burmester, AbbVie, Bristol-Myers Squibb, Lilly, MSD, Novartis, Pfizer, Roche, Sandoz, and UCB, 2, 5; E. Naredo, AbbVie, Roche, Bristol-Myers Squibb, Pfizer, UCB, Lilly, Novartis, Janssen, and Celgene GmbH, 8,AbbVie Inc., 9; I. Lagunes Galindo, AbbVie Inc., 1, 3; Y. Zhang, AbbVie Inc., 1, 3; X. Wang, AbbVie Inc., 1, 3; M. Hojnik, AbbVie Inc., 1, 3; P. G. Conaghan, AbbVie, Bristol-Myers Squibb, Lilly, Novartis, Pfizer, and Roche, 5, 8.

To cite this abstract in AMA style:

Emery P, Burmester GR, Naredo E, Lagunes Galindo I, Zhang Y, Wang X, Hojnik M, Conaghan PG. Low Inflammation on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis That Achieved Sustained Clinical Remission on Adalimumab [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/low-inflammation-on-magnetic-resonance-imaging-in-patients-with-rheumatoid-arthritis-that-achieved-sustained-clinical-remission-on-adalimumab/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-inflammation-on-magnetic-resonance-imaging-in-patients-with-rheumatoid-arthritis-that-achieved-sustained-clinical-remission-on-adalimumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.